Avenue Therapeutics, Inc.
ATXI
$0.80
$0.045.19%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -34.02% | -37.41% | 13.53% | -9.32% | -28.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -77.06% | -60.80% | -48.61% | -24.68% | 52.61% |
| Operating Income | 77.06% | 110.52% | 48.61% | 24.68% | -52.61% |
| Income Before Tax | 77.58% | 112.18% | 57.28% | -352.67% | -701.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 77.58% | 112.18% | 57.28% | -352.67% | -701.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -18.18% | -33.33% | -33.33% | -34.78% | -15.38% |
| Net Income | 77.80% | 112.44% | 57.33% | -341.25% | -684.79% |
| EBIT | 77.06% | 110.52% | 48.61% | 24.68% | -52.61% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 88.84% | -92.76% | 95.95% | 67.03% | -139.55% |
| Normalized Basic EPS | 88.91% | 104.43% | 91.93% | -134.54% | -138.88% |
| EPS Diluted | 88.84% | -92.76% | 95.95% | 67.03% | -139.55% |
| Normalized Diluted EPS | 88.91% | 104.43% | 91.93% | -134.54% | -138.88% |
| Average Basic Shares Outstanding | 98.95% | 184.81% | 428.61% | 579.81% | 1,378.93% |
| Average Diluted Shares Outstanding | 98.95% | 184.81% | 428.61% | 579.81% | 1,378.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |